The planned length of participation in the study for each subject is up to approximately 110 weeks (from screening through completion of follow-up). This includes:
- Screening/baseline period of up to 4 weeks
- Double-blind, placebo-controlled treatment period of 48 weeks
- Open-label extension treatment period of 48 weeks ( all subject to enter a 48-week open label extension period and receive active treatment with lademirsen (SAR339375))
- Post-treatment follow-up period of 10 weeks
How understandable was the trial content above?
Hard to understand
Easy to understand
